BLUE STAR LTD.

Blue Star Ltd has announced a Board of Directors meeting scheduled for Thursday, October 29, 2026. The primary agenda is to consider and approve the Un-audited Standalone and Consolidated Financial Results for the Second Quarter and Half Year ended September 30, 2026. Additionally, the company has informed about the closure of the trading window for Designated Persons from October 1, 2026, to October 31, 2026, in compliance with SEBI's Prohibition of Insider Trading Regulations. This intimation is also available on the company's website.

Blue Star Ltd has announced that its Board of Directors will convene on October 29, 2026, to consider and approve the un-audited standalone and consolidated financial results for the second quarter and half-year ended September 30, 2026. Concurrently, the company has informed about the closure of the trading window for designated persons from October 1, 2026, to October 31, 2026, in compliance with SEBI's Prohibition of Insider Trading Regulations. This announcement is made in accordance with SEBI's Listing Obligations and Disclosure Requirements.

Blue Star Ltd has provided an update on arbitration proceedings initiated by W.J. Towell & Co LLC (WJT) concerning the management of Blue Star Oman Electro Mechanical Company. The Arbitrator previously issued an award in favor of Blue Star, dismissing all claims made by WJT, which initially amounted to OMR 103,18,000 and was later revised to OMR 2,11,80,748 (approx. Rs 461.74 crores). WJT has now approached the Dubai Court of Appeal seeking annulment of this award. Blue Star believes the grounds for annulment are baseless and will make submissions before the court. The company considers this a subsequent development and not a material update, as annulment proceedings do not reconsider the merits of the award.

Blue Star Ltd announced the completion of the sale and transfer of the MedTech business of its wholly-owned subsidiary, Blue Star Engineering & Electronics Limited (Blue Star E&E), to Cyrix Healthcare Private Limited. The transfer was effective September 1, 2026. The MedTech business, which deals with high-end medical diagnostic equipment and services, was sold on a slump sale basis. The consideration is payable in tranches, with the final payment due by March 31, 2027. The MedTech division contributed Rs 42.13 crores in income for FY26, representing approximately 0.33% of Blue Star's consolidated income, and had a net worth of approximately Rs 7.11 crores as of March 31, 2026.

Blue Star Engineering & Electronics Limited, a wholly owned subsidiary of Blue Star Ltd, has executed a Business Transfer Agreement (BTA) with Cyrix Healthcare Private Limited to sell its MedTech division. The division, which deals in high-end medical diagnostic equipment and services, generated ₹42.13 crores in income for FY26, representing 0.33% of the company's consolidated income. The net worth of the division was approximately ₹7.11 crores as of March 31, 2026. The sale, structured as a slump sale, is expected to be completed by March 31, 2027, with a consideration of up to ₹40 crores. Cyrix Healthcare is not part of Blue Star's promoter group, and the transaction is not considered a related party transaction.

Blue Star Ltd reported a 13.3% revenue growth to ₹3,377.92 crore for Q1FY27, driven by a 15.1% increase in Segment I (Electro-Mechanical Projects & Commercial Air Conditioning Systems). However, margins were impacted by commodity price escalation, currency depreciation, and inventory issues, leading to a 23.7% drop in PBT before exceptional items and a 15.1% decline in net profit to ₹102.53 crore. The company saw significant inflow of Data Center MEP project orders, contributing to a 13.5% growth in the carried-forward order book to ₹7,764.38 crore. Despite investing in capacity and R&D, capital employed decreased due to improved working capital, and the company maintained a net cash position of ₹900.25 crore.

Blue Star Limited conducted its 78th Annual General Meeting (AGM) on August 6, 2026, via Video Conferencing. The meeting transacted ordinary business, including the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026. Shareholders approved the declaration of a final dividend of ₹8.5 per equity share. The re-appointment of Mr. Rajiv R Lulla as a Director was also on the agenda. The AGM proceedings were conducted in compliance with relevant regulations, with remote e-voting facilities provided to shareholders.

Blue Star Ltd reported a 13.3% year-on-year growth in consolidated revenue for Q1FY27, reaching ₹3,377.92 crores. Despite robust revenue expansion, operating profit (EBITDA) declined by 12.5% to ₹174.95 crores, with EBITDA margins narrowing to 5.2% from 6.7% in Q1FY26. This margin compression was attributed to rising input costs and other headwinds. Profit Before Tax (PBT) fell by 23.7% to ₹125.62 crores, and Net Profit decreased to ₹102.51 crores. The company saw strong order inflow in Data Centre MEP projects and robust bookings in Commercial Air Conditioning. The Unitary Products segment also grew, though margins were impacted by inventory liquidation pressures. The order book grew by 13.5% to ₹7,764.38 crores.

Blue Star Ltd announced the outcome of its Board Meeting held on August 6, 2026. The Board approved and took on record the Un-audited Standalone and Consolidated Financial Results for the First Quarter ended June 30, 2026, along with the Limited Review Reports. Additionally, the Board approved the appointment of Mr. Nikhilesh Panchal as an Independent Director for a term of five years, subject to shareholder approval via Postal Ballot. The meeting commenced at 10:00 a.m. and concluded at 2:15 p.m. The financial results and related reports are enclosed with the filing and available on the company's website.

Blue Star Ltd announced the appointment of Mr. Nikhilesh Panchal as an Additional Director, designated as an Independent Director. This appointment, approved by the Board of Directors on August 6, 2026, is subject to shareholder approval via postal ballot. Mr. Panchal will serve a term of five consecutive years commencing August 14, 2026. He is a practicing lawyer with over 35 years of experience in corporate law, capital markets, and intellectual property, and is not related to any other director. The company will seek shareholder approval through a postal ballot.